Cargando…
Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives
Cisplatin (CDDP), carboplatin (CP), and oxaliplatin (OXP) are three platinating agents clinically approved worldwide for use against a variety of cancers. They are canonically known as DNA damage inducers; however, that is only one of their mechanisms of cytotoxicity. CDDP mediates its effects throu...
Autores principales: | Forgie, Benjamin N., Prakash, Rewati, Telleria, Carlos M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793759/ https://www.ncbi.nlm.nih.gov/pubmed/36499737 http://dx.doi.org/10.3390/ijms232315410 |
Ejemplares similares
-
Cancer cell repopulation after therapy: which is the mechanism?
por: Prakash, Rewati, et al.
Publicado: (2023) -
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
por: Kumar, Smriti, et al.
Publicado: (2011) -
The Metallurgy of Platinized Gold Cast Clasps
por: Elisberg, M.
Publicado: (1922) -
The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity.
por: Ohkawa, K., et al.
Publicado: (1988) -
Pain in Platin-Induced Neuropathies: A Systematic Review and Meta-Analysis
por: Brozou, Vasiliki, et al.
Publicado: (2017)